Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 3:29 AM
Ignite Modification Date:
2025-12-25 @ 3:29 AM
NCT ID:
NCT00944905
Eligibility Criteria:
Inclusion Criteria:
* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2
* Criteria specific to each tumor type:
* For Clear cell renal cell carcinoma (ccRCC): advanced or recurrent disease. Must have failed at least 1 prior systemic therapy
* For B-cell non-Hodgkin's lymphoma (B-NHL): Must have failed at least 1 prior systemic therapy
* Measurable disease criteria by tumor type:
* For ccRCC: At least 1 unidimensional measurable lesion
* For B-NHL: At least 1 bidimensionally measurable lesion
* Prior therapies for advanced/recurrent ccRCC or relapsed/refractory B-NHL or have become intolerant to a systemic therapy
* Provide archived or fresh tumor tissue for CD70 status. Subjects must be CD70+
* Provision of fresh tissue (pre-treatment and on-treatment) for exploratory analysis is mandatory for at least 5 and a maximum of 10 B-NHL subjects
Exclusion Criteria:
* Prior therapy with an anti-CD70 antibody
* History of severe hypersensitivity reactions to other monoclonal antibodies
* Active or untreated central nervous system lymphoma
* Active infection (viral, bacterial, or fungal)
* Evidence of bleeding diathesis or coagulopathy
* Active autoimmune disease requiring immunosuppressive therapy
* Known current drug or alcohol abuse
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT00944905
Study Brief:
Protocol Section:
NCT00944905